2025年7月17日 · Therapeutic advances include refinements in surgical approaches for both localized and metastatic disease, while systemic treatment options are expanding beyond …

2024年2月21日 · This narrative review contributes to understanding the molecular basis of ACC, summarizes the current management approaches from a multidisciplinary perspective, and …

2019年10月1日 · Taken together, these statistics highlight a critical need for novel therapeutic strategies to fight ACC, contingent on a deeper understanding of the molecular basis of this …

2024年12月24日 · Unresectable ACC relies heavily on mitotane-based therapies. Additional local therapies have been used but lack a recommended regimen. Recurrence rates are high, …

The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: …

2025年3月12日 · In the following review, we outline emerging targeted therapies, such as mTOR inhibitors and tyrosine kinase inhibitors (TKIs), which show favorable preclinical and clinical …

2006年1月1日 · Evidence Synthesis: Multiple new modalities that may enhance the future treatment of ACC were identified. They include the following: combating drug resistance, …

2025年7月3日 · The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic …

2021年2月1日 · Due to its adrenolytic action, mitotane has become the first-line medical treatment in patients with aggressive adrenocortical carcinoma.

2025年7月3日 · Adrenocortical carcinoma (ACC) is a rare but aggressive cancer with a poor prognosis that imposes an immense burden on those ill-fated to be touched by this cancer. …